Abstract
Metabolic syndrome (MS) is a modern medical condition characterized by central obesity, hyperglycaemia, hypercholesterolemia and hypertension. The beneficial effects of mushrooms in lowering the symptoms of MS were known from both traditional and conventional medicine. Edible mushrooms, their extracts, polysaccharide fractions and isolated compounds possessed hypoglycaemic, cholesterol and triglyceride lowering ability, hypotensive effects, as well as weight managing activity by influencing satiety. The most active compounds are polysaccharides, called β-glucans, as well as lectines and small compounds such as eritadenin, triterpenes, sterols and phenolic compounds.
Keywords: Antihypertensive, hypoglycaemic, hypolipidemic, mushrooms, metabolic syndrome, weight loss.
Current Topics in Medicinal Chemistry
Title:Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Tatjana Kundakovic and Marina Kolundzic
Affiliation:
Keywords: Antihypertensive, hypoglycaemic, hypolipidemic, mushrooms, metabolic syndrome, weight loss.
Abstract: Metabolic syndrome (MS) is a modern medical condition characterized by central obesity, hyperglycaemia, hypercholesterolemia and hypertension. The beneficial effects of mushrooms in lowering the symptoms of MS were known from both traditional and conventional medicine. Edible mushrooms, their extracts, polysaccharide fractions and isolated compounds possessed hypoglycaemic, cholesterol and triglyceride lowering ability, hypotensive effects, as well as weight managing activity by influencing satiety. The most active compounds are polysaccharides, called β-glucans, as well as lectines and small compounds such as eritadenin, triterpenes, sterols and phenolic compounds.
Export Options
About this article
Cite this article as:
Kundakovic Tatjana and Kolundzic Marina, Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome, Current Topics in Medicinal Chemistry 2013; 13 (21) . https://dx.doi.org/10.2174/15680266113136660196
DOI https://dx.doi.org/10.2174/15680266113136660196 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Biochemical Markers of Renal Function
Current Medicinal Chemistry α-Fibrinogenases
Current Drug Targets - Cardiovascular & Hematological Disorders Applied Pathology for Interventions of Coronary Chronic Total Occlusion
Current Cardiology Reviews Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets Evidence that Cortical Dopamine is a Co-Transmitter in Noradrenergic Neurons
Current Psychiatry Reviews Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Recent Advances in Perioperative Anesthetic Management Update on the Role of Vasopressin and its Effects on Outcomes
Current Pharmaceutical Design Targeted Inhibition of AKT in Pancreatic Cancer
Current Cancer Therapy Reviews Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets